Loading clinical trials...
Loading clinical trials...
A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Endovascular Coiling.
Conditions
Interventions
Clazosentan 5 m/h
Clazosentan 15 mg/h
+1 more
Locations
145
United States
Glendale Adventist Medical Center
Glendale, California, United States
UCSF Medical Centre
San Francisco, California, United States
Stanford Hospital and Clinis
Stanford, California, United States
Colorado Neurological Institute
Englewood, Colorado, United States
Yale Univerity School of Medicine
New Haven, Connecticut, United States
University of South Florida
Tampa, Florida, United States
Start Date
July 1, 2009
Primary Completion Date
October 1, 2010
Completion Date
January 1, 2011
Last Updated
July 9, 2018
NCT07160088
NCT07307508
NCT06409364
NCT04566991
NCT04507178
NCT04490161
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions